Reliability and validity of the Apathy Evaluation Scale.
R S Marin, R C Biedrzycki, S Firinciogullari
https://pubmed.ncbi.nlm.nih.gov/1754629Actively Recruiting
Led by Medical University of South Carolina · Updated on 2025-10-22
40
Participants Needed
1
Research Sites
N/A
Total Duration
Apathy, characterized by loss of motivation and withdrawal, commonly affects many people after a stroke and significantly lowers quality of life for both patients and their caregivers. This research aims to evaluate if a fast-delivered form of repetitive transcranial magnetic stimulation (rTMS) targeting the medial prefrontal cortex (mPFC) can be safe, tolerable, and helpful for treating apathy following stroke. The study is a randomized, double-blind trial designed to explore efficacy, safety, and other impacts beyond apathy in stroke survivors. The trial compares two groups: one receiving active accelerated intermittent theta burst stimulation (iTBS) rTMS to the left dorsal medial prefrontal cortex (dmPFC), and the other receiving a sham version that mimics the procedure without active stimulation. Participants receive 12 sessions daily over six treatment days within two weeks, totaling 72 sessions and 43,200 pulses. Brain imaging and neuronavigation guide precise treatment delivery, and the study uses advanced devices to ensure blinding and standardized targeting. Participants will be assessed at baseline, immediately after treatment, and one month later through clinical tests, brain MRIs, and questionnaires evaluating apathy and cognition. Safety is monitored throughout each treatment day, and participant retention and treatment acceptability are tracked. Outcomes include changes in apathy symptoms, cognition, and depression, as well as any adverse events, with the total involvement spanning the treatment period plus follow-up assessments.
CONDITIONS
Accelerated rTMS vs. Sham for Stroke Apathy
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 weeks
Participants receive accelerated iTBS-rTMS or sham stimulation targeting the left dmPFC using neuronavigation for 6 days over 2 weeks.
6 treatment days with 12 sessions per day (3-4 hours each day)
Duration - 1 month
Participants undergo clinical assessments to measure changes in apathy, cognition, and treatment acceptability after treatment completion.
Visits at immediately post-treatment and 1-month post-treatment follow-up
Total: 1 location
1
Medical University of South Carolina Brain Stimulation Lab
Charleston, South Carolina, United States, 29403
Actively Recruiting
P
Parneet Grewal, MD
L
Lisa McTeague, PhD
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
R S Marin, R C Biedrzycki, S Firinciogullari
https://pubmed.ncbi.nlm.nih.gov/1754629Kaitlin B Casaletto, Anya Umlauf, Jennifer Beaumont...
https://pubmed.ncbi.nlm.nih.gov/26030001P Sockeel, K Dujardin, D Devos...
https://pubmed.ncbi.nlm.nih.gov/16614016Ziad S Nasreddine, Natalie A Phillips, Valérie Bédirian...
https://pubmed.ncbi.nlm.nih.gov/15817019Richard Levy, Bruno Dubois
https://pubmed.ncbi.nlm.nih.gov/16207933Ricardo E Jorge, Sergio E Starkstein, Robert G Robinson
https://pubmed.ncbi.nlm.nih.gov/20540829Naohiko Santa, Hiroshi Sugimori, Kenji Kusuda...
https://pubmed.ncbi.nlm.nih.gov/19008681C Le Heron, M A J Apps, M Husain
https://pubmed.ncbi.nlm.nih.gov/28689673Nobuyuki Sasaki, Takatoshi Hara, Naoki Yamada...
https://pubmed.ncbi.nlm.nih.gov/28578330Paul E Holtzheimer, William M McDonald, Mustafa Mufti...
https://pubmed.ncbi.nlm.nih.gov/20734360